Get the Stockscreener App
15.20
5.35%
-0.86
After Hours:
15.50
0.30
+1.97%
Syndax Pharmaceuticals Inc stock is traded at $15.20, with a volume of 2.08M.
It is down -5.35% in the last 24 hours and down -2.25% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$16.06
Open:
$16.19
24h Volume:
2.08M
Relative Volume:
0.93
Market Cap:
$1.31B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-5.1351
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-7.32%
1M Performance:
-2.25%
6M Performance:
+36.20%
1Y Performance:
-20.54%
1-Day Range:
$15.01
$16.28
1-Week Range:
$15.01
$16.80
52-Week Range:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
15.20 | 1.38B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.9%Here's What Happened - MarketBeat
Real time pattern detection on Syndax Pharmaceuticals Inc. stockJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - newser.com
Heatmap analysis for Syndax Pharmaceuticals Inc. and competitors2025 EndofYear Setup & AI Driven Stock Movement Reports - newser.com
Syndax Pharmaceuticals Inc. stock momentum explainedMarket Rally & Risk Managed Investment Strategies - newser.com
Syndax Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
Evaluating Syndax Pharmaceuticals Inc. with trendline analysis2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Order flow analysis tools used on Syndax Pharmaceuticals Inc.July 2025 Action & Pattern Based Trade Signal System - newser.com
Will Syndax Pharmaceuticals Inc. stock see insider buying2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-10 04:00:50 - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Analyzing drawdowns of Syndax Pharmaceuticals Inc. with statistical toolsPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Published on: 2025-10-09 05:04:06 - newser.com
Should you hold or exit Syndax Pharmaceuticals Inc. nowJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentValue Traps to Avoid & Small Investment Portfolio - earlytimes.in
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Technical analysis overview for Syndax Pharmaceuticals Inc. stockJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Research Analysts Offer Predictions for SNDX FY2027 Earnings - MarketBeat
Will October's FDA Decision Be A Shot In The Arm For Revuforj's Expansion? - RTTNews
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Rallies & Short-Term High Return Strategies - newser.com
Measuring Syndax Pharmaceuticals Inc.’s beta against major indices2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Comparing Syndax Pharmaceuticals Inc. in custom built stock radarsProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision - Yahoo Finance
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - The Sunday Guardian
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - MarketScreener
Does Syndax Pharmaceuticals Inc. qualify in momentum factor screeningStop Loss & Daily Entry Point Trade Alerts - newser.com
138,900-Share Grant: Syndax Awards to 10 New Employees; Options Vest Monthly Under Inducement Plan - Stock Titan
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
What analysts say about Syndax Pharmaceuticals Inc stockEarnings Revision Updates & Minimize Portfolio Damage with Warnings - earlytimes.in
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from BTIG Research - MarketBeat
Risk On: Can Syndax Pharmaceuticals Inc stock double in the next yearGap Down & Real-Time Buy Zone Alerts - خودرو بانک
Multiple Insiders Sold Syndax Pharmaceuticals Shares Presenting Weak Signs For Investors - 富途牛牛
Syndax Pharmaceuticals Nears Critical Regulatory Milestone - AD HOC NEWS
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Syndax Pharmaceuticals Inc Stock (SNDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Sep 08 '25 |
Sale |
16.41 |
157,307 |
2,582,021 |
298,661 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):